🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Suzhou Genhouse Bio clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Suzhou Genhouse Bio as lead sponsor. Synced 26 Sep 2026
5Current trials
2Recruiting now
1Drug in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Suzhou Genhouse Bio is the lead sponsor of 5 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Tagrisso. The most-studied condition is Advanced Solid Tumor Cancer.

ClinicalTrials.gov trials by status

  • Recruiting240%
  • Not yet open240%
  • Active, closed120%

Trials by phase

  • Phase 1/2240%
  • Phase 1240%
  • Phase 2120%
01

Clinical trials sponsored by Suzhou Genhouse Bio

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
NCT06306456 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer With EGFR Mutation
Drug: Tagrisso
Phase 1/2 Recruiting 2024-03 China
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors
NCT06796699 · ClinicalTrials.gov ↗ · Advanced Solid Tumors With MTAP Gene Deletion
Phase 1 Recruiting 2025-03 China
A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors
NCT07446725 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer
Phase 1/2 Not yet open 2026-02 China
Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation
NCT07318649 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors
Phase 2 Not yet open 2025-12 China
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.
NCT07260513 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer
Phase 1 Active, closed 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Suzhou Genhouse Bio trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Suzhou Genhouse Bio trials

4 conditions
Advanced Solid Tumor Cancer2Non-Small Cell Lung Cancer With EGFR Mutation1Locally Advanced or Metastatic Solid Tumors1Advanced Solid Tumors With MTAP Gene Deletion1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China52

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Tumor Cancer

SponsorTrials
HC Biopharma2
Calico Life Sciences1
LaNova Medicines1

Sponsors with the most current trials registered for this condition.

06

Questions about Suzhou Genhouse Bio trials

How many clinical trials does Suzhou Genhouse Bio sponsor?

Suzhou Genhouse Bio is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Suzhou Genhouse Bio trials recruiting?

Yes. 2 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Suzhou Genhouse Bio testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Tagrisso (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.